Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EBITDA: 2019-2025

Historic EBITDA for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -$81.0 million.

  • Kymera Therapeutics' EBITDA fell 38.48% to -$81.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.6 million, marking a year-over-year decrease of 81.22%. This contributed to the annual value of -$224.8 million for FY2024, which is 57.68% down from last year.
  • Kymera Therapeutics' EBITDA amounted to -$81.0 million in Q3 2025, which was down 6.13% from -$76.3 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' EBITDA ranged from a high of -$12.5 million in Q4 2023 and a low of -$81.0 million during Q3 2025.
  • Moreover, its 3-year median value for EBITDA was -$51.7 million (2023), whereas its average is -$53.5 million.
  • As far as peak fluctuations go, Kymera Therapeutics' EBITDA skyrocketed by 63.22% in 2023, and later plummeted by 494.77% in 2024.
  • Over the past 5 years, Kymera Therapeutics' EBITDA (Quarterly) stood at -$34.4 million in 2021, then climbed by 1.49% to -$33.9 million in 2022, then spiked by 63.22% to -$12.5 million in 2023, then slumped by 494.77% to -$74.2 million in 2024, then plummeted by 38.48% to -$81.0 million in 2025.
  • Its last three reported values are -$81.0 million in Q3 2025, -$76.3 million for Q2 2025, and -$64.2 million during Q1 2025.